Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M
Biomark Res. 2024; 12(1):137.
PMID: 39538363
PMC: 11565275.
DOI: 10.1186/s40364-024-00676-9.
Yang P, Liu S, Li C, Zhang W, Wang J, Chen Y
Ann Hematol. 2024; 103(7):2381-2391.
PMID: 38165416
DOI: 10.1007/s00277-023-05597-5.
de Haan L, de Groen R, de Groot F, Noordenbos T, van Wezel T, van Eijk R
Virchows Arch. 2023; 485(4):643-654.
PMID: 37851120
PMC: 11522076.
DOI: 10.1007/s00428-023-03676-6.
Hill H, Jain P, Ok C, Sasaki K, Chen H, Wang M
Cancer Res Commun. 2023; 3(8):1435-1446.
PMID: 37538987
PMC: 10395375.
DOI: 10.1158/2767-9764.CRC-23-0083.
Wang Y, Jain P, Locke F, Maurer M, Frank M, Munoz J
J Clin Oncol. 2023; 41(14):2594-2606.
PMID: 36753699
PMC: 10489553.
DOI: 10.1200/JCO.22.01797.
Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?.
Beitinjaneh A, Kaufman A, Wang Y, Jain P, Srour S, Wang M
Curr Treat Options Oncol. 2022; 23(11):1614-1625.
PMID: 36227407
PMC: 9557996.
DOI: 10.1007/s11864-022-01020-9.
Genomic profiling for clinical decision making in lymphoid neoplasms.
de Leval L, Alizadeh A, Bergsagel P, Campo E, Davies A, Dogan A
Blood. 2022; 140(21):2193-2227.
PMID: 36001803
PMC: 9837456.
DOI: 10.1182/blood.2022015854.
Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?.
Hammons L, Fenske T
J Pers Med. 2022; 12(7).
PMID: 35887631
PMC: 9324979.
DOI: 10.3390/jpm12071134.
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
Burkart M, Karmali R
J Pers Med. 2022; 12(3).
PMID: 35330376
PMC: 8954159.
DOI: 10.3390/jpm12030376.
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y
J Clin Invest. 2021; 132(3).
PMID: 34882582
PMC: 8803323.
DOI: 10.1172/JCI153283.
Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre T, Cheah C, Wang M
Blood. 2021; 139(5):666-677.
PMID: 34679161
PMC: 9710495.
DOI: 10.1182/blood.2021013326.
Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C, Zheng Y, Feng Y, Cao X, Xu C
Sci Rep. 2021; 11(1):11896.
PMID: 34099776
PMC: 8185106.
DOI: 10.1038/s41598-021-91433-7.
-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy.
Chen L, Mu W, Gu J, Xiao M, Huang L, Zheng M
Diagnostics (Basel). 2021; 11(5).
PMID: 34066756
PMC: 8151854.
DOI: 10.3390/diagnostics11050844.
Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
Assis-Mendonca G, Fattori A, Rocha R, Lourenco G, Delamain M, Nonogaki S
BMC Cancer. 2021; 21(1):209.
PMID: 33648463
PMC: 7919095.
DOI: 10.1186/s12885-021-07891-9.
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill H, Qi X, Jain P, Nomie K, Wang Y, Zhou S
Blood Adv. 2020; 4(13):2927-2938.
PMID: 32598477
PMC: 7362354.
DOI: 10.1182/bloodadvances.2019001350.
Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion.
McCall R, Pang C, Pettenati M
Case Rep Hematol. 2020; 2020:9185432.
PMID: 32257467
PMC: 7106885.
DOI: 10.1155/2020/9185432.
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
Jain P, Zhang S, Kanagal-Shamanna R, Ok C, Nomie K, Gonzalez G
Blood Adv. 2020; 4(6):1038-1050.
PMID: 32191807
PMC: 7094021.
DOI: 10.1182/bloodadvances.2019001396.
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.
Pararajalingam P, Coyle K, Arthur S, Thomas N, Alcaide M, Meissner B
Blood. 2020; 136(5):572-584.
PMID: 32160292
PMC: 7440974.
DOI: 10.1182/blood.2019002385.
Genetic alterations in B cell lymphoma subtypes as potential biomarkers for noninvasive diagnosis, prognosis, therapy, and disease monitoring.
Esmeray E, Kucuk C
Turk J Biol. 2020; 44(1):1-14.
PMID: 32123491
PMC: 7049453.
DOI: 10.3906/biy-1908-23.
Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.
Buege M, Kumar A, Dixon B, Tang L, Pak T, Orozco J
Ann Pharmacother. 2020; 54(9):879-898.
PMID: 32079411
PMC: 8330616.
DOI: 10.1177/1060028020909117.
